Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Salvia Divinorum/Substance Use Disorders (SUD)

Salvia Divinorum for Substance Use Disorders (SUD)

8 papers and 0 clinical trials exploring salvia divinorum as a treatment for substance use disorders (sud).

CompoundDiterpenoid

Salvia Divinorum

A specialized plant species that produces salvinorin A, a potent and selective kappa-opioid agonist with intense, short-lived effects.

Full Salvia Divinorum profile
IndicationAmong the world’s largest preventable health burdens

Substance Use Disorders (SUD)

Addiction is one of the oldest hopes for psychedelic medicine, going back to LSD trials for alcoholism in the 1950s. Today psilocybin is the workhorse, with positive trials in alcohol, tobacco and cocaine use disorders, and the cross-substance signal is real. But the picture is mixed rather than settled: a major alcohol trial was null, the studies are small, and almost all of them struggle to keep patients unaware of whether they got the drug. This page is the hub; alcohol, opioid and tobacco use disorders have their own dedicated pages.

Full Substance Use Disorders (SUD) profile

Academic Research

8 papers
Paywallindividual

Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A

This fMRI study explores the effects of psilocybin (a serotonergic psychedelic) and Salvinorin-A (a kappa-opioid receptor agonist) on resting-state functional connectivity (FC) in nonhuman primates. It reveals both drugs influence FC around the thalamus, claustrum, prefrontal cortex (PFC), and default mode network (DMN), with similarities and differences noted between them.

Published
June 25, 2024
Journal
ACS Chemical Neuroscience
Authors
Bagdasarian, F. A., Hansen, H. D., Chen, J., Yoo, C. H., Placzek, M. S., Hooker, J. M., Wey, H. Y.
Open Accessindividual

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

A combined reanalysis of five datasets (N = 3817) found that among psychedelic-experienced individuals only past use of psilocybin reliably predicts self-reported nature relatedness (with weaker, less reliable effects for DMT), and this pattern holds when psychedelic-naïve participants are included. Among participants exclusively experienced with psilocybin, greater use frequency was associated with higher nature relatedness, suggesting future work should investigate psilocybin-specific pharmacological or contextual factors.

Published
January 5, 2023
Journal
Journal of Psychopharmacology
Authors
Forstmann, M., Kettner, H. S., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., Luke, D.
Paywallindividual

The kappa opioid receptor and the sleep of reason: Cortico-subcortical imbalance following salvinorin-A

Acute administration of salvinorin-A, a highly selective kappa opioid receptor agonist, produced dramatic dissociative psychotomimetic effects without dysphoria and revealed a cortico–subcortical imbalance. Neurophysiologically this was reflected by widespread cortical hypoperfusion and reduced cortical EEG alpha (with increased delta and gamma) alongside increased blood flow in medial temporal regions (amygdala, hippocampal gyrus) and the cerebellum.

Published
September 19, 2021
Journal
International Journal of Neuropsychopharmacology
Authors
Ona, G., Sampedro, F., Romero, S., Valle, M., Camacho, V., Migliorelli, C., Mañanas, M. Á., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido H Msc, M., Riba, J.
Open Accessindividual

The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain

In a placebo-controlled fMRI study, acute inhaled salvinorin A altered human functional connectivity — most prominently attenuating default mode network connectivity during peak effects, reducing brainwide dynamic functional connectivity and (non-significantly) increasing entropic connectivity. Dynamic-connectivity patterns, especially early in the scan, reliably classified the salvinorin A state, and the overall connectivity profile resembles that reported for other hallucinogens.

Published
October 2, 2020
Journal
Scientific Reports
Authors
Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T. E., Griffiths, R. R., Barrett, F. S.
Paywallmeta

The Use of Salvia divinorum from a Mazatec Perspective

This book chapter (2018) investigates the use of salvia divinorum by the Mazatec people. Applications discussed include headaches (pain), inflammation, addiction, and depression. Next to medicinal and psychotherapeutic applications, the inner exploration (recreational) purposes are also discussed.

Published
April 29, 2018
Journal
Plant Medicines Healing and Psychedelic Science
Authors
Maqueda, A. E.
Open Accessmeta

A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics

This review (2016) examines the psychoactive properties and therapeutic potential of Salvinorin A, a kappa-opioid receptor agonist that is the bioactive constituent of the indigenous plant Salvia divinorum. Next to highly potent psychoactive properties as a dissociative hallucinogen, preliminary scientific evidence also indicates it may have broad-range therapeutic applications for treating addiction, inflammation, pain, and depression.

Published
May 1, 2017
Journal
Phytochemistry
Authors
Cruz, A. P. M., Domingos, S., Gallardo, E., Martinho, A.

Clinical Trials

0 trials

No clinical trials have been tagged with both Salvia Divinorum and Substance Use Disorders (SUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Salvia Divinorum papers Search all Substance Use Disorders (SUD) trials Full Salvia Divinorum profile Full Substance Use Disorders (SUD) profile